{"disease":{"id":"advanced-clear-cell-renal-cell-carcinoma","name":"advanced clear cell renal cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07000149","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1116,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01668784","title":"Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":821,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07383441","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":718,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT07227415","title":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04374877","title":"Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Coherus Oncology, Inc.","has_results":false},{"nct_id":"NCT04071223","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03679767","title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02974738","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07097935","title":"Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05663710","title":"Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05665361","title":"Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02118337","title":"A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT05012371","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06863311","title":"Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Karie Runcie","has_results":false},{"nct_id":"NCT03284385","title":"Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06942104","title":"Imaging of Solid Tumors Using 18F-TRX","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT06866262","title":"Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT05361720","title":"Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false},{"nct_id":"NCT01521715","title":"First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT06245915","title":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"Arsenal Biosciences, Inc.","has_results":false},{"nct_id":"NCT07218692","title":"RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":35,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07128680","title":"Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06730932","title":"A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05122546","title":"CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05440045","title":"A Clinical Study of 6MW3211 in Patients With Renal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Mabwell (Shanghai) Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT03829111","title":"CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06870279","title":"A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06399419","title":"CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Osel, Inc.","has_results":false},{"nct_id":"NCT07123090","title":"A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Stephanie Berg","has_results":false},{"nct_id":"NCT06191796","title":"Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06964958","title":"177LuPSMA in Renal Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT07510334","title":"VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04904302","title":"Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01538238","title":"pazopanib_NCRCC,Ph2 STUDY","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03260504","title":"Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT05176288","title":"Avelumab, Palbociclib and Axitinib in Advanced RCC","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Bradley A. McGregor, MD","has_results":false}],"total":38},"guidelines":[],"source":"Drug Landscape verified database"}